Compare MobilEye Global Inc (MBLY) vs Oscar Health Inc (OSCR) Price & Performance

Mobileye (MBLY) trades at $8.80, up 0.57% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat estimates with EPS of $0.19 versus $0.06 expected, driven by an R&D grant, while revenue reached $508 million (Bloomberg, 2026-07-23). The company faces leadership transition as CEO Amnon Shashua steps down after 27 years, amid expanded robotaxi and ADAS initiatives, including a new supply deal with Stellantis (Business Wire, 2026-07-21).

Outlook: Analyst consensus is bullish with a $11.40 price target (61.5% buy ratings), but risks include persistent net losses (-$4.1B in 2026), high EV/EBITDA of 43.25, and execution challenges under new leadership. The stock offers upside if robotaxi adoption accelerates, but profitability concerns and market volatility pose headwinds.

Oscar Health (OSCR) trades at $29.61, up 7.01% today, with technical indicators showing a bearish trend but oversold RSI signals. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.1 per share, and raised its full-year outlook amid membership growth and cost control. Revenue surged 70% year-over-year to $4.9 billion for the first half of 2026, driving a net income turnaround to $551 million for the full year 2026.

The outlook is positive with robust revenue growth and profitability improvements, though risks include competitive pressures and reliance on Obamacare policies. Analysts have a consensus price target of $32.50, suggesting moderate upside, but hold ratings dominate due to execution risks.